Biomedicina – Medicina di Precisione by Xagena

ImmunoTerapia: ImmunoTherapy: The New Frontiers in Medicine

OncoBase.Rid

 

IDO pathway inhibitor Indoximod in combination with Pembrolizumab, an anti-PD1 checkpoint inhibitor, for patients with advanced melanoma

The indoleamine 2,3-dioxygenase ( IDO ) pathway is a key counter-regulatory mechanism that normally inhibits immune responses when appropriate. In the setting of cancer, IDO pathway-mediated immune …


 

Advanced lung cancer: five-year survival rate for Nivolumab-treated patients much higher than historical rate

Treatment with the immune checkpoint inhibitor Nivolumab ( Opdivo ) has yielded durable responses in some patients with advanced non-small cell lung cancer ( NSCLC ), with a five-year survival rate of …


 

Axalimogene filolisbac is an active therapy in metastatic cervical cancer

Data from the GOG-0265 study were presented at the Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer. GOG-0265 is a single arm, phase 2 trial evaluating Axalimogene filolisbac for …


 

Cancer treatment with anti-PD-1 / PD-L1 agents: PD-L1 expression is not a biomarker for patient selection

Strategies to help improve the efficacy of the immune system against cancer represent an important innovation, with recent attention having focused on anti-programmed death (PD)-1 / PD-ligand 1 (L1) m …


 

Metastatic urothelial carcinoma: safety, clinical activity, and PD-L1 expression of Avelumab, an anti-PD-L1 antibody

Avelumab is a fully human anti-PD-L1 IgG1 antibody being investigated in multiple clinical trials. Safety and clinical activity of Avelumab as a second-line therapy in patients with metastatic uro …

ImmunoTerapia: ImmunoTherapy: The New Frontiers in Medicineultima modifica: 2018-04-10T23:04:20+02:00da tiberis1

Lascia un commento

Se possiedi già una registrazione clicca su entra, oppure lascia un commento come anonimo (Il tuo indirizzo email non sarà pubblicato ma sarà visibile all'autore del blog).
I campi obbligatori sono contrassegnati *.